EMA recommends dacomitinib for EGFR activating mutation-positive NSCLC
medwireNews: The selective EGFR–tyrosine kinase inhibitor dacomitinib has been granted a positive opinion for first-line use in European patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR activating mutations.
Dacomitinib was demonstrated to offer significantly longer progression-free survival than gefitinib for patients with treatment-naïve disease in the ARCHER 1050 trial.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group